Genmab A/S (NASDAQ:GMAB) Shares Sold by Millennium Management LLC

Millennium Management LLC lessened its holdings in Genmab A/S (NASDAQ:GMAB - Free Report) by 19.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 380,995 shares of the company's stock after selling 92,934 shares during the quarter. Millennium Management LLC owned approximately 0.06% of Genmab A/S worth $9,574,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Russell Investments Group Ltd. increased its holdings in Genmab A/S by 137.7% in the first quarter. Russell Investments Group Ltd. now owns 939 shares of the company's stock valued at $28,000 after buying an additional 544 shares during the last quarter. GAMMA Investing LLC increased its holdings in Genmab A/S by 194.0% in the first quarter. GAMMA Investing LLC now owns 1,135 shares of the company's stock valued at $34,000 after buying an additional 749 shares during the last quarter. Allspring Global Investments Holdings LLC purchased a new position in Genmab A/S in the first quarter valued at $43,000. Barometer Capital Management Inc. purchased a new position in Genmab A/S in the fourth quarter valued at $121,000. Finally, Headlands Technologies LLC increased its holdings in Genmab A/S by 1,702.8% in the second quarter. Headlands Technologies LLC now owns 5,138 shares of the company's stock valued at $129,000 after buying an additional 4,853 shares during the last quarter. Hedge funds and other institutional investors own 7.07% of the company's stock.

Genmab A/S Trading Up 0.3 %

Shares of GMAB traded up $0.06 during mid-day trading on Wednesday, hitting $23.65. 1,510,583 shares of the company's stock were exchanged, compared to its average volume of 582,576. Genmab A/S has a fifty-two week low of $23.24 and a fifty-two week high of $35.88. The firm has a market capitalization of $15.64 billion, a P/E ratio of 19.71, a P/E/G ratio of 0.73 and a beta of 0.98. The business's 50 day moving average is $26.36 and its two-hundred day moving average is $27.44.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.07). Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. The business had revenue of $779.50 million for the quarter, compared to analyst estimates of $734.60 million. On average, equities research analysts forecast that Genmab A/S will post 1.27 earnings per share for the current year.

Analyst Ratings Changes

Several research firms recently commented on GMAB. BTIG Research increased their target price on Genmab A/S from $46.00 to $47.00 and gave the company a "buy" rating in a report on Thursday, June 27th. JPMorgan Chase & Co. reaffirmed a "neutral" rating on shares of Genmab A/S in a report on Tuesday, August 20th. Redburn Atlantic started coverage on Genmab A/S in a report on Tuesday. They set a "buy" rating on the stock. HC Wainwright reaffirmed a "buy" rating and set a $50.00 price objective on shares of Genmab A/S in a report on Friday, September 20th. Finally, Morgan Stanley reaffirmed an "equal weight" rating and set a $31.00 price objective on shares of Genmab A/S in a report on Wednesday, September 11th. Two analysts have rated the stock with a sell rating, three have given a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $45.20.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.